- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 87,190 | 20.06.24 14:37:46 | +0,130 | +0,15% | 0,000 | 0,000 | 86,860 | 87,060 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 968,400 | 20.06.24 17:20:37 | +4,600 | +0,48% | 0,000 | 0,000 | 966,200 | 963,800 |
